Findings conducted by The Observer, a Kampala based newspaper, indicate that instances of expired medicines and health supplies in Uganda is still rampant, and that expired drugs were still on the shelves at various health facilities during a recent survey conducted by the newspaper.
In October 2015, the World Health Organization reported that the Millennium Development Goal (MDG) to halt and reverse TB incidence (MDG 6c) was achieved on a worldwide basis, in each of WHO’s six regions and in 16 of the WHO’s 22 high-burden countries. While this progress is commendable, recent evidence suggests the trend may be reversing.
Since entering the New Funding Model (NFM) as an early applicant in 2013, Zimbabwe has been a unique case for Global Fund investments. The country submitted a single HIV concept note in April 2013 (before integrated HIV/TB concept notes were encouraged), was granted $311.2 million, and began implementation in January 2014.
Civil society principal recipients (PRs) from across Africa recently gathered in Nairobi, Kenya to consolidate their collective knowledge and experiences and establish a formal community of practice. From 29-31August, 65 participants from 20 African countries demonstrated their commitment to strengthening the implementation of Global Fund grants through increased collaboration and peer learning.
“End It for Good,” is the rallying call for the Global Fund’s Fifth Replenishment conference, to be held in Montreal, Canada on 16-17 September 2016. Millions of lives have been saved and infections averted, and tremendous progress has been made in the fight against AIDS, TB, and malaria. Yet, there is still no greater global health challenge for humanity.
Report calls for a fully funded Global Fund and a focus on the leadership of networks of key populations
To achieve the Sustainable Development Goals (SDGs) requires not only a fully funded Global Fund, but also an approach that focuses strongly on the leadership of networks of key and vulnerable populations to deliver results.
With progressively stricter patent protections, the costs for new treatments continue to rise. It is a global problem that affects countries across income levels, but it is particularly challenging for poor and transitioning economies.